Actinic Keratosis Treatment Market Report

Actinic Keratosis Treatment Market Analysis, Market Size, Therapeutic Class Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Published Date: ---
  • Base Year for Estimate: ---
  • Report ID: GVR5656
  • Format: Electronic (PDF)
  • Historical Data: ---
  • Number of Pages: 0

The global actinic keratosis (AK) treatment market is projected to exhibit strong growth through the forecast period, driven by the broad availability and rising adoption of generic drugs. The treatment of actinic keratosis as a preventive strategy for complicated comorbidities, such as basal cell carcinoma, squamous cell carcinoma, and nonmelanoma skin cancer is a key driving force for market growth.

Actinic keratosis, or solar keratosis, is a dermatologic condition caused due to ultraviolet (UV) radiation exposure. AK causes scaly and crusty growth on the skin, and may lead to skin cancer if left untreated. It is estimated that actinic keratosis accounts for more than 50% skin-related squamous cell carcinomas. AK is the most prevalent class of precancerous skin lesions. The most commonly affected areas are the scalp, face, ears, neck, shoulder, forearms, and hands.

The AK treatment market has been classified into the following drug classes: nucleoside metabolic inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), immune response modifiers, and photoenhancers. Products containing 5-fluorouracil (FU), such as Carac, Efudex, Fluoroplex, and Tolak are the chemotherapeutic agents used for AK treatment. Aldara, Zyclara, and Picato modify immune response as their mechanism of action. Solaraze, a topical therapy combining hyaluronic acid with diclofenac, is a key revenue generator for this market.

The market is further segmented into hospitals, private clinics, homecare, and others on the basis of end use. Geographically, the market has been divided into North America, Europe, Latin America, Asia Pacific, and MEA. Based on regional shares, North America led the AK therapeutic space and we estimate this trend to continue through the forecast period.

Some of the major players in the global actinic keratosis market include Bausch Health Companies Inc., Leo Pharma A/S, Bausch Health Companies Inc., Novartis International AG, Biofrontera Inc., Sun Pharmaceutical Industries Limited, Mylan N.V., Hill Dermaceuticals, Inc., TOLMAR Inc, Perrigo, Inc., Apotex Inc, and Almirall, S.A.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified